Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect

Texto completo
Autor(es):
Mostrar menos -
Oliveira, Natalia Kronbauer [1, 2] ; Frank, Luiza Abrahao [3] ; Squizani, Eamim Daidre [1] ; Reuwsaat, Julia Catarina Vieira [1] ; Marques, Barbara Machado [1] ; Motta, Heryk [1] ; Garcia, Ane Wichine Acosta [1] ; Kinskovski, Uriel Perin [1] ; Barcellos, Vanessa Abreu [1] ; Schrank, Augusto [1, 4] ; Pohlmann, Adriana Raffin [5, 3] ; Staats, Charley Christian [1, 4] ; Guterres, Silvia Staniscuaski [3] ; Vainstein, Marilene Henning [1, 4] ; Kmetzsch, Livia [1, 4]
Número total de Autores: 15
Afiliação do(s) autor(es):
[1] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Porto Alegre, RS - Brazil
[2] SUNY Stony Brook, Dept Microbiol & Immunol, Stony Brook, NY 11794 - USA
[3] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, Porto Alegre, RS - Brazil
[4] Univ Fed Rio Grande do Sul, Dept Biol Mol & Biotecnol, Porto Alegre, RS - Brazil
[5] Univ Fed Rio Grande do Sul, Inst Quim, Dept Quim Organ, Porto Alegre, RS - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: European Journal of Pharmaceutical Sciences; v. 162, JUL 1 2021.
Citações Web of Science: 0
Resumo

Cryptococcus neoformans is the etiological agent of cryptococcal meningoencephalitis. The recommended available treatment has low efficiency, with high toxicity and resistance as recurrent problems. In the search of new treatment protocols, the proposal of new pharmacological approaches is considered an innovative strategy, mainly nanotechnological systems considering fungal diseases. The antiarrhythmic drug amiodarone has demonstrated antifungal activity against a range of fungi, including C. neoformans. Here, considering the importance of calcium storage mediated by transporters on cryptococcal virulence, we evaluated the use of the calcium channel blocker amiodarone as an alternative therapy for cryptococcosis. C. neoformans displayed high sensitivity to amiodarone, which was also synergistic with fluconazole. Amiodarone treatment influenced some virulence factors, interrupting the calcium-calcineurin signaling pathway. Experiments with murine cryptococcosis models revealed that amiodarone treatment increased the fungal burden in the lungs, while its combination with fluconazole did not improve treatment compared to fluconazole alone. In addition, we have developed different innovative nanotechnological formulations, one of which combining two drugs with different mechanisms of action. Lipid-core nanocapsules (LNC) loaded with amiodarone (LNCAMD), fluconazole (LNCFLU) and both (LNCAMD+FLU) were produced to achieve a better efficacy in vivo. In an intranasal model of treatment, all the LNC formulations had an antifungal effect. In an intraperitoneal treatment, LNCAMD showed an enhanced anticryptococcal effect compared to the free drug, whereas LNCFLU or LNCAMD+FLU displayed no differences from the free drugs. In this way, nanotechnology using amiodarone formulations could be an effective therapy for cryptococcal infections. (AU)

Processo FAPESP: 14/50928-2 - INCT 2014: Nanotecnologia Farmacêutica: uma abordagem transdisciplinar
Beneficiário:Maria Vitória Lopes Badra Bentley
Modalidade de apoio: Auxílio à Pesquisa - Temático